A topical cream developed by Rubedo Life Sciences reduced participants' skin biological age by roughly two years on average after one month of use, according to data the Mountain View, California–based biotech company presented at the Aging Research and Drug Discovery meeting in Boston earlier this month. The experimental treatment targets senescent cells — damaged cells that stop dividing but don't die — and represents one of the first human trials testing whether clearing these "zombie" cells can visibly reverse skin aging. The company tested its approach in people with inflammatory skin conditions, finding reductions not just in biological age markers but also in disease symptoms.
The trial enrolled 11 participants with atopic dermatitis, the most widespread form of eczema, who applied the cream for four weeks. An independent analysis by Mitra Bio, which designed the aging clock used to measure results, calculated the average two-year drop in skin biological age based on methylation patterns — chemical modifications to DNA that change over time and are used to estimate how well tissue is aging compared to calendar age. One participant saw their skin age fall by more than 11 years. Separately, Rubedo measured a 10 percent rise in a collagen type linked to skin structure and elasticity, along with decreases in markers tied to inflammation. In a different study of 18 people with actinic keratosis — a sun-damage condition that produces rough, scaly patches and can progress to skin cancer — the same cream led to a 46 percent drop in total lesions after one month.
"Our idea is to find ways to change the trajectory of how we age," says Marco Quarta, Rubedo's cofounder and chief scientific officer. The treatment works by temporarily blocking a protein called GPX4, which acts as a survival gatekeeper for cells. By switching off GPX4 briefly, the drug makes senescent cells more vulnerable to ferroptosis, a controlled form of cell death, while helping nearby stressed cells that aren't senescent to recover. Biological age estimates don't necessarily prove that tissue has become functionally younger, and Eric Verdin, president and CEO of the Buck Institute for Research on Aging, noted he'd "be a little circumspect about what these clocks really measure" given their proliferation.
Rubedo is now studying the same drug for psoriasis and sun-damaged skin, and will soon add androgenetic alopecia — hereditary hair loss — to its trial list. CEO Frederick Beddingfield, formerly chief medical officer at Allergan where he launched Botox, sees room for a lower-strength over-the-counter version aimed at general skin aging that would compete with retinol. The company is also formulating the compound as a pill to test whether it can treat metabolic conditions tied to aging. Anthony Rossi, a dermatologist at Memorial Sloan Kettering Cancer Center, called the science novel but cautioned the work remains early-stage, noting that some senescent cells play helpful roles such as blocking cancer progression and that it will be important to see how the treatment affects people with healthy skin. For now, he said, "the best anti-aging routine right now is sleep, a good diet, and exercise." Companies racing to prove they can slow human aging face a fundamental test: whether eliminating one mechanism of cellular damage translates to meaningful improvements in how people function and feel, not just how biomarkers shift. If Rubedo's approach holds up in larger studies across different tissues, it could establish senescent cell removal as a credible intervention beyond the lab — though distinguishing cosmetic benefits from genuine health gains will remain the harder question.